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ABSTRACT
Biology has taught us that a protein as abundantly made and con-
served among species as Tamm–Horsfall protein (THP or uro-
modulin) cannot just be a waste product serving no particular
purpose. However, for many researchers, THP is merely a nui-
sance during urine proteome profiling or exosome purification
and for clinicians an enigmatic entity without clear disease impli-
cations. Thanks to recent human genetic and correlative studies
and animal modeling, we now have a renewed appreciation of
this highly prevalent protein in not only guarding urinary ho-
meostasis, but also serving as a critical mediator in systemic inter-
organ signaling. Beyond a mere barrier that lines the tubules, or a
surrogate for nephron mass, mounting evidence suggests that
THP is a multifunctional protein critical for modulating renal ion
channel activity, salt/water balance, renal and systemic inflamma-
tory response, intertubular communication, mineral crystalliza-
tion and bacterial adhesion. Indeed, mutations in THP cause a
group of inherited kidney diseases, and altered THP expression is
associated with increased risks of urinary tract infection, kidney
stone, hypertension, hyperuricemia and acute and chronic kidney
diseases. Despite the recent surge of information surrounding
THP’s physiological functions and disease involvement, our
knowledge remains incomplete regarding how THP is normally
regulated by external and intrinsic factors, how precisely THP de-
ficiency leads to urinary and systemic pathophysiology and in
what clinical settings THP can be used as a theranostic biomarker
and a target for modulation to improve patient outcomes.
Keywords: AKI, biomarkers, gene polymorphism, immunol-
ogy, nephrolithiasis
INTRODUCTION
Tamm–Horsfall protein (THP) or uromodulin (gene name
UMOD) is a 90-kDa protein produced almost exclusively in the
kidney by the epithelial cells lining the thick ascending limb
(TAL) of the loop of Henle and early distal tubules [1–3]. This
protein was initially discovered by Tamm and Horsfall in 1950
as an inhibitor of viral hemagglutination in the urine [4].
Although THP has since been assigned many more functions,
few have been validated clinically or experimentally.
Nonetheless, its highly restricted renal expression, extraordi-
nary abundance and conservation among species support im-
portant biological functions and fuel a steady interest for both
researchers and clinicians [1].
Initial biochemical characterization of THP was met with
tremendous technical difficulties [3]. Due to its heavy glycosyla-
tion, which accounts for 30–40% of its total molecular mass and
low isoelectric point (pI 5.00), this acidic protein is poorly
stained by Coomassie Blue and hardly visible on sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE). Because of its high propensity to self-aggregate and its
susceptibility to proteases, measurements of THP in solutions
and fluids such as the urine can be highly variable [5]. The TAL
cells, where THP is synthesized, are terminally differentiated,
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polarized cells that are difficult to cultivate in vitro, and this has
hampered in-depth investigation into the biosynthesis,
posttranslational modification, intracellular trafficking, mem-
brane targeting and release into the urine and bloodstream [6].
Notwithstanding these difficulties, the progress made in study-
ing THP is quite substantial and is starting to fundamentally
transform our understanding of the multifaceted role of THP in
regulating kidney physiology, response to injury and cross talk
of the kidney with other organ systems [1, 7–9].
In fact, THP has been assigned a role in the following func-
tions: water impermeability of the thick ascending loop of
Henle [2], ion-channel activity in TAL and early distal tubular
cells [10–13], calcium and magnesium homeostasis [14, 15],
cross talk with proximal tubules within the kidney [7, 16, 17],
regulation of systemic granulopoiesis [9], homeostasis of mono-
nuclear phagocytes in the kidney [18], susceptibility and re-
sponse to kidney injury [17–19], susceptibility and response to
urinary tract infection (UTI) [20–22] and kidney stone patho-
genesis [23, 24]. In addition, mutations within the coding re-
gion of UMOD have been causally linked to a group of
autosomal dominant, progressive kidney diseases collectively
called uromodulin-associated kidney disease (UAKD) [25–27].
Recent genetic studies have identified single-nucleotide poly-
morphisms (SNPs) in the upstream regulatory region of THP
that are associated with varying risk of hypertension and
chronic kidney disease (CKD), suggesting that this protein plays
an even broader role in regulating kidney function [28–30].
This review will synthesize key aspects of THP biology and fo-
cuses predominantly on several novel areas of advancements
(in the context of our existing knowledge of THP) while point-
ing out some areas of controversies. We refer readers to previ-
ous and recent comprehensive reviews for the topics not
covered in this review due to space constraints [1, 31]. For the
sake of consistency, we will use ‘THP’ as an abbreviation for
Tamm–Horsfall protein or uromodulin and reserve UMOD
only when discussing the human gene.
THP BIOLOGY
Protein structure: sequence and domain composition
THP is a glycosylphosphatidylinositol (GPI) anchor-linked
protein of remarkable structure and unique properties [3]. The
precursor protein is composed of 640 amino acids based on the
complementary DNA sequence (Figure 1A) [32]. Motifs identi-
fied in the THP primary sequence include a signal peptide
directing its entry into the secretory pathway (residues 1–24),
one epidermal growth factor-like (EGF-like) domains (residues
31–64), two calcium-binding EGF-like domains (residues 65–
107 and 108–149), a D8C domain containing eight conserved
cysteines (residues 199–287), a fourth EGF-like domain (resi-
dues 295–319) [33], one zona pellucida (ZP)-like domain (resi-
dues 334–585), eight potential N-linked glycosylation sites and
a stretch of hydrophobic amino acids at the C-terminus that
acts as a signal for GPI anchorage (residue 614). There are 48
cysteine residues involved in the formation of 24 disulfide brid-
ges. The predicted EGF-like domains are believed to mediate
THP protein interactions and the ZP-like domain promotes
self-aggregation and polymerization.
Biosynthesis and cellular trafficking
Since THP has a leader peptide and is a GPI-anchored
plasma membrane protein, its synthesis and intracellular traf-
ficking proceed through the well-established secretory pathway.
During biosynthesis, the THP precursor is cotranslationally
translocated into the endoplasmic reticulum (ER) where the
signal peptide is removed and the protein is glycosylated on
seven of its eight potential glycosylation sites [34], disulfide
bonds are formed and a preformed GPI anchor is added on its
C-terminus, most likely on S614 [35]. Following this addition,
the membrane-bound THP is transported to the Golgi appara-
tus where the high mannose glycans are trimmed and complex
glycans added. Both the mature glycans and GPI anchor are
sorting signals, directing the protein predominantly to the api-
cal membrane of the TAL epithelial cells [36, 37]. It is proposed
that THP reaches the luminal side of the plasma membrane in a
polymerization-incompetent conformation retained by the in-
teraction of two hydrophobic motifs, one located within the ZP
domain, called the internal hydrophobic patch (IHP, residues
430–462), and the other positioned between the ZP domain and
the GPI anchor site, called the external hydrophobic patch
(EHP, residues 598–607) [33, 38]. Proteolytic cleavage by a re-
cently identified hepsin protease, at residue F587, disturbs the
hydrophobic interaction between the IHP and EHP generating a
polymerization-capable monomer that is subsequently assem-
bled into polymeric filaments [39, 40]. THP is secreted in
the urine as a high-molecular weight polymer (Mr ¼ 1–10 
106Da) that under electron microscopy analysis appears as a
fibril matrix that can assume a gel-like structure depending on
the ionic strength [41]. Urinary THP monomer is composed
of 563 amino acids and, depending on its glycosylation status,
migrates as an 80–90 kDa band on reducing SDS-PAGE.
Monomeric forms of THP in the urine have been reported af-
ter treatment with urea [42]. A truncated form lacking a por-
tion of the ZP polymerization domain can be isolated from the
urine [18]. This form is predominantly monomeric, although
it can also form dimers, as it retains the N-terminal part of the
ZP domain [43].
The rate limiting step in THP maturation is thought to be
processing in the ER, due to its complex tertiary structure deter-
mined by its high number of cysteine residues (48.7% of amino
acid content), all engaged in the formation of intramolecular di-
sulfide bridges [44]. In the ER, glycosylation is initiated on
seven of eight potential N-linked glycosylation sites. In the
Golgi complex, all glycan chains are modified to complex poly-
antennary sialic acid–terminated carbohydrates, with the ex-
ception of N274, which retains a high-mannose moiety [34].
This unmodified high-mannose moiety is remarkably con-
served and is present in THP of all the species examined (see
further). Evidence for O-linked glycosylation has also been
reported [45]. Thus the molecular weight of THP is significantly
contributed (30%) by glycosylation and such high carbohy-
drate content is believed to be important for the physicochemi-
cal properties and function of THP.
In addition to this canonical apical targeting, THP also sorts,
to a lesser degree, to the basolateral domain of the tubular epi-
thelial cells, as demonstrated by confocal immunofluorescence
34 R. Micanovic et al.
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and electron microscopy [16, 46, 47]. Basolaterally sorted THP
is released in the interstitium where it enters circulation and
becomes part of the serum proteome, where it can be easily
measured by immunoassays [48–51]. The mechanisms that
govern basolateral release of THP are not yet clear, but the cir-
culating form of THP is predominantly monomeric, as shown
recently by Micanovic et al. [18]. It is unclear why circulating
THP, despite being full length, does not aggregate. This could
be partially due to its low concentration in the serum compared
with urine (20–50 ng/mL versus 20–50mg/mL, respectively).
Other explanations include an alternative cleavage site at the C-
terminus that retains the EHP sequence and interferes with the
aggregating property of the ZP domain, similar to what was
shown in cell culture models [33, 38, 40]. Recent work
by Tokonami et al. [52] showed a role for the calcium-sensing
receptor in regulating THP trafficking within TAL cells and api-
cal release in the urine. Whether these recent findings also
translate into changes in basolateral release will need to be
determined.
THP EXPRESSION, LOCALIZATION AND
SECRETION
THP is primarily expressed in cells of the TALs of Henle and
early distal tubules, but it is absent from macula densa cells [46,
53, 54]. This pattern of expression of THP has been primarily
established in rodents and to a lesser extent in human kidneys.
Interestingly, we consistently observe focal expression of THP
in some glomeruli in humans (Figure 1B). This is also observed
in a publically available atlas database using multiple antibodies
applied to different sets of human kidney tissue [55] and was
also reported by McGiven et al. [56] in 1978 in a series of hu-
man kidney biopsies. The significance of this occasional
presence of THP in the Bowman space or in the glomerular tuft
in human kidneys is unclear, but certainly deserves future in-
vestigation since glomerular function appeared to be somewhat
affected by THP deficiency [8], and certain THP mutations can
lead to glomerulocystic kidney disease, an inherited kidney dis-
ease characterized by cystic dilatation of the Bowman’s space
and collapse of the glomerular tuft [26].
Regulation of THP expression is poorly understood. Recent
in silico phylogenetic footprinting analysis showed that UMOD
promoter is likely regulated by a large network of interacting
transcription factors [57]. One of those transcription factors,
hepatocyte nuclear factor 1 b has been shown to activate THP
expression [58]. SNP variants in the upstream regulatory region
of the UMOD gene also affect the expression of THP [50, 59,
60]. Other factors such as dietary salt and diuretics also affect
the expression of THP [61, 62]. These latter effects are likely
due to the interplay between THP and ion transporters targeted
by diuretics. The synthesis of THP is dynamic and likely varies
based on physiological and pathological stressors and nephron
mass [63]. For example, the expression of THP increases in
early diabetes even without evidence of kidney injury [64, 65].
THP expression can also fluctuate even when kidney function is
normal, as demonstrated by varied THP measurements both in
the serum and urine [50, 66, 67]. Although it has been suggested
that the production of THP reaches a plateau beyond a glomer-
ular filtration rate (GFR) of 90mL [66], the variance of THP
remains quite high, suggesting that with normal kidney func-
tion, the impact of GFR or nephron mass on THP levels is re-
duced compared with other regulatory factors that modulate
THP expression and production.
While urinary THP is excreted at a rate of 30–60mg/day
with normal kidney function [1, 66], the range of THP in the
FIGURE 1: THP structure and expression. (A) Schematic representation of the primary amino acid structure of THP and its various domains.
The top shows THP precursor with a signal peptide and 640 amino acids and a GPI anchoring site (614). The bottom shows mature urinary
THP that is released after cleavage by hepsin. Two specific sequences (IHP and EHP) are important to prevent intracellular THP polymeriza-
tion through the ZP domains. EHP is cleaved during THP release in the urine. See text for specific abbreviations. (B) In addition to its expres-
sion in the TALs, THP can be occasionally detected in the glomerulus by confocal immunofluorescence (top 2 panels are from a deceased
donor nephrectomy) and immunohistochemistry [bottom panels are from the Human Protein Atlas (https://www.proteinatlas.org)]. The
findings are reproduced in three different tissues using three different antibodies. Arrowheads in the images show THP staining in the
glomerulus.
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serum is less well established (range 30–500ng/mL) and several
recent studies measured serum THP in a few cohorts [50, 51,
67–71]. Both urine and serum THP are directly associated with
kidney function [49]. However, THP expression and secretion
are very dynamic and can change rapidly in response to patho-
physiological conditions, as we discuss below. Also, the fact that
THP is regulated by a network of transcription factors [57]
strongly suggests that this protein is under intricate regulation
[72] and that the changes in its level result from complex
interactions.
THE MULTIFACETED ROLE OF THP IN
MAINTAINING HOMEOSTASIS
Under normal circumstances, THP appears to regulate various
molecular targets within the cells where it is produced and on
cells downstream of TAL through its release in the urine or in
the interstitium and then the circulation (Figure 2,
Homeostasis). Clearly, alterations in the functioning of THP,
whether due to a decrease in its expression, mutations or im-
pairment in its downstream targets, could underlie the patho-
genesis of many kidney diseases (Figure 2, Disease). Based on
studies of THP/ mice, it is now established that THP defi-
ciency, independent of kidney function, creates a state of in-
flammation, both systematically and in the kidney [1, 7–9].
This is now also supported by multiple human clinical studies
that measured the level of serum and urine THP [67, 68, 72].
An interesting phenomenon is a concentration gradient of
THP from the urine (highest) toward the serum (lowest). There
is likely another concentration gradient of THP in the intersti-
tium between the medulla (where TAL density is increased)
and the cortex [7]. In addition to regulating intricate physiolog-
ical functions (altering a gradient signals stress), gradients are
essential for chemotaxis, and it is likely that such a THP gradi-
ent may be important in the homeostasis of mononuclear
phagocytic cells (MPCs) in the inner stripe of the outer medulla,
since THP knockout mice have a reduced MPC population in
this region [18]. The various roles attributed to THP are sum-
marized in Figure 2 and listed below.
Within the TAL and early distal convoluted tubule (DCT),
THP regulates water permeability [2] and activity of the sodium
potassium chloride cotransporter type 2 (NKCC2), renal outer
medullary potassium and sodium chloride cotransporter chan-
nels [10–13]. Evidence for such regulation has been established
experimentally, especially in knockout mice. This has important
implications in disease associated with THP deficiency. For ex-
ample, a recent study by Liu et al. [10] showed that chronic
THP deficiency leads to a compensatory increase in proximal
reabsorption of solutes accompanied by upregulation of urate
transporters, initially triggered by reduced apical translocation
of NKCC2 in the TAL cells. These changes lead to hypertension
and hyperuricemia, which are phenotypic features consistently
present in advanced CKD, a state of relative THP deficiency
[67, 68, 71].
In the urine, THP can regulate calcium and magnesium
reabsorption in DCT and connecting segment cells by modulat-
ing the abundance of transient receptor potential cation chan-
nel subfamily V member 5 (TRPV5) and transient receptor
potential cation channel subfamily M member 6 channels on
these cells [14, 15]. This has implications on divalent cation ho-
meostasis and urolithiasis as discussed below.
In the renal interstitium, THP can target multiple cell types
within that microenvironment. By accessing the basolateral do-
main of epithelial cells [16], THP inhibits pro-inflammatory sig-
naling from the neighboring proximal tubules, such as
neutrophil–chemokine release [17] and production of interleu-
kin (IL)-23, which can stimulate the release of IL-17 systemi-
cally and enhancement of granulopoiesis through granulocyte
colony-stimulating factor [9]. Therefore changes in THP levels
in the interstitium could be considered as stress or danger sig-
nals that will trigger a response from the epithelium that cas-
cades into a more systemic reaction [7].
THP will also interact with immune cells in the renal inter-
stitium. In fact, THP appears to be a significant regulator of the
FIGURE 2: THP function in health and disease. This annotated drawing summarizes how THP is an important guardian of homeostasis (left
side) both in the cells where it is produced (TALs and early DCTs) and also in target cells reached through the urine or via the interstitium and
bloodstream. Disturbance in THP function either through deficiency or mutations can lead to disease by altering its function at various sites
(right side). CNTs: connecting tubules; PTs: proximal tubules.
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abundance and phagocytic activity of resident MPCs [18]. It is
likely that this role has important implications in the immune
balance within the renal interstitium that can be perturbed dur-
ing injury.
Since THP is released by the kidney in the circulation, do cir-
culating THPs have a distant effect on other organs? This is a
likely scenario because an effect of THP on epithelial and im-
mune cells may have far-reaching impacts well beyond the kid-
neys. The extent that THP impacts nonkidney organ systems
may be highly dependent on its levels in the circulation. Several
recent studies have shown that THP levels in the serum are in-
versely correlated with markers of inflammation, such as
C-reactive protein and IL-1b, independent of kidney function
and even in patients with normal kidney function [67, 68, 72].
The fact that a high THP level in the serum is associated with
protection from cardiovascular mortality and kidney injury, in-
dependent of kidney function, strongly supports that THP has a
positive impact on the homeostasis of the entire organism [50].
THP IN SPECIFIC DISEASE STATES
The role of THP in specific disease states has been studied in
several animal models and clinical settings and reviewing these
data is important to understand the behavior of THP and inter-
pret changes in its level during systemic and/or kidney disease.
Since THP has pleiotropic effects both within the cells where it
is produced and on distant targets, it is reasonable to anticipate
that changes in THP production will depend on whether the
kidneys, and specifically THP-producing cells, are affected by
the disease. In addition, our current knowledge (including sev-
eral unpublished observations) suggests that the production of
THP is dynamic and is affected by pathophysiological stressors
[53, 72, 73]. Therefore it is logical to interpret the changes in
THP levels in the serum and/or urine depending on the pres-
ence of a systemic illness and whether the disease affects the
kidney and causes acute kidney injury (AKI).
Systemic illness and inflammation
Because of its protective, counterinflammatory functions
and its role in maintaining homeostasis, it is expected that THP
production by the kidney will compensatorily increase in sys-
temic illness without kidney injury [53]. Examples would be
stress response to infections, transient hemodynamics changes
and fight/flight responses [1, 7]. When THP production is in-
creased in that setting, it is likely that the kidney is counteract-
ing uncontrolled systemic inflammation through inhibition of
cytokine/chemokine signaling or via activation and polarization
of macrophages.
AKI
Studies using animal models of AKI, namely the ischemia–
reperfusion injury (IRI) model, helped elucidate the role of
THP in AKI. During AKI, THP production is significantly di-
minished both at the RNA and protein level, as shown bymulti-
ple groups and confirmed in few human studies [1]. Therefore
AKI is a state of THP deficiency [74]. The mechanisms through
which THP expression is regulated during AKI are not fully un-
derstood [74].
Renal IRI in THP knockout mice is significantly more severe
than in wild-type animals [16, 17, 19]. The injury is associated
with increased neutrophil-activating inflammatory signaling in
S3 tubules, leading to tubular necrosis in these segments.
Therefore THP produced in the TAL inhibits chemokine sig-
naling and the susceptibility of neighboring proximal tubules to
injury, supporting the presence of a THP-dependent TAL–S3
tubular cross-talk phenomenon [1, 75]. Translocation of THP
from the basolateral surface of TAL toward the basolateral do-
main of neighboring S3 tubules, the interstitium and circulation
is important to suppress subsequent inflammation and begin
recovery [16]. The effect of THP on neutrophil infiltration is
likely to also involve regulation of the IL-23/IL-17 axis, whereby
THP deficiency seen in AKI will stimulate granulopoiesis [9].
Furthermore, THP is important in macrophage migration,
phagocytic activity, alternative polarization and healing. The
latter may be important in promoting a swift transition toward
a recovery phase [18]. Therefore a prolonged state of THP defi-
ciency during AKI will likely lead to a more severe and persis-
tent inflammatory state. Indeed, administration of exogenous
THP after AKI mitigates subsequent injury and hastens recov-
ery [18].
CKD
Based on our understanding of the function of THP inmain-
taining homeostasis and regulating inflammation and immune
cell activation, it is likely that THP is a defender of the kidney
against CKD [1]. Indeed, high baseline THP, independent of
kidney function, is protective from subsequent decline in GFR
[67, 76]. In fact, the synthesis of THP per functioning nephron
unit is increased in CKD [49] (THP per unit GFR, the uromo-
dulin index as we proposed previously [1]), that is, when the
kidney is under attack. This was elegantly demonstrated by
Thornley et al. [49], who showed that THP excretion per millili-
ter of creatinine clearance had a higher range in patients with
CKD compared with normal subjects. However, despite in-
creased production by intact nephrons, fibrosis will cause addi-
tional nephrons to drop out, leading to an absolute decrease in
THP production in progressive CKD. The results will be that
total THP levels drop as CKD progresses and GFR declines [49,
51, 71]. Conversely, in patients with very early CKD or with
kidney disease without an apparent decrease in kidney function,
THP synthesis will be increased. This has been reported in early
diabetes without GFR impairment (in human and animal mod-
els of diabetes) or in patients prior to the onset of CKD [59, 64,
65, 67, 77–79]. This effect was also demonstrated to be indepen-
dent of renal mass [49, 77].
Interpreting changes in THP levels with progressive or ad-
vanced CKD can be challenging, as the surviving functional
nephron units are under stress and will likely continue to over-
produce THP. At the same time, the surviving nephron units are
progressively diminished. The net sum of these two opposing
tendencies and their effects on the levels of circulating THP are
difficult to predict and likely to introduce variability. It may be
more useful in these situations to follow 24-h urine THP meas-
urements normalized by unit of clearance. In fact, significant tu-
bular atrophy observed in kidney biopsies correlated with a
Uromodulin (Tamm–Horsfall protein) 37
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decrease in urinary THP excretion per unit GFR, suggesting that
with more advanced disease, the synthesis of THP per nephron
unit will eventually decline [49]. In these instances, decreased
24-h THP excretion per GFR unit likely implies a depletion of
tubular reserves and progression to end-stage disease [49].
THP in urinary homeostasis and disease
It is not entirely surprising that THP plays major roles in the
urinary tract [80], given the fact that the bulk of THP made by
the TAL cells is excreted in the urine. Thus urinary THP binds
in a dose-dependent manner to the FimH adhesin of type 1-
fimbriated uropathogenic Escherichia coli, which causes up to
85% of all uncomplicated UTIs [81, 82]. The binding is medi-
ated specifically by the evolutionally conserved, unmodified
high-mannose residues of the THP, resulting in competitive in-
hibition and preventing E. coli from adhering to their cognate
urothelial receptor, that is, uroplakin Ia, which bears the identi-
cal high-mannose receptor. There is some evidence that the
unmodified mannoses on the soluble receptor (THP) and the
immobilized receptor (uroplakin Ia) are co-evolved during evo-
lution [2, 42]. The same principle might apply to the complex
sugars shared by THP and uroplakin III [83]. Some of these
predictions have already panned out in THP/ mice, which
are significantly more prone to experimentally induced UTIs
than wild-type [20–22]. A previously suspected role of THP in
inhibiting urinary calcium crystallization has also been vali-
dated in THP/ mice. Spontaneous intrarenal crystals com-
prised of hydroxyapatite have been detected in knockout mice
by histochemical staining and transmission electron micros-
copy and confirmed by infrared spectroscopy [23, 24, 84].
These crystals are deposited on the basement membrane, con-
centrated in the papillary region and not associated with overt
inflammation—features resembling early stages of nephroli-
thiasis in idiopathic calcium oxalate stone–forming patients.
The THP/ mice are also highly prone to renal calcium crys-
tallization induced by experimental hyperoxaluria. Such crystals
are primarily intratubular. Although the exact mechanisms for
THP to inhibit renal calcification remain to be elucidated, THP
likely interferes with multiple steps during urolithiasis, includ-
ing crystal formation, growth, aggregation and epithelial attach-
ment. Furthermore, the effect of THP on distal calcium
reabsorption through its effect on TRPV5 will reduce urinary
calcium and may mitigate the risk for supersaturation of cal-
cium oxalate and calcium phosphate [15].
An immunomodulatory role for THP in the urine has also
received experimental support. THP accomplishes this role,
possibly by binding to various cytokines, serving as a trap or
sink and hence reducing the urinary levels of cytokines [8].
Although the disease implications of THP-mediated cytokine
modulation have yet to be defined, reduced levels of THP have
already been associated with UTI and kidney stone risks in
humans. In one cohort, kidney stone formers were found to
contain 30% less urinary THP than the nonstone-forming con-
trols [85]. In another cohort, a THP variant, that is, the
rs4293393-T allele, which is associated with high THP, is pro-
tective of kidney stones [86]. Similar correlation between high
urinary THP levels and low risks of UTI has also been
demonstrated in older community-dwelling adults by one of
the coauthors of this review [87]. Even in individuals with nor-
mal levels of THP, deficiency in high-mannose- and complex-
type glycosylation may still play a role in the susceptibility to
UTI and kidney stones, respectively [85, 88].
CLINICAL STUDIES USING THP AS A
BIOMARKER
The last decade has seen a number of studies published that
have evaluated the role of serum and urine THP as a potential
biomarker. These have included its use in the prognostication
of progressive GFR decline, incident ESRD, posttransplant graft
loss, all-cause mortality, cardiovascular disease (CVD) events
and UTIs.
Urine THP
Data from two large cohorts of older adults demonstrate
that higher THP levels are associated with significantly lower
odds of loss of kidney function over nearly a decade [76, 89].
Given that THP may serve as a marker of tubular reserve, its
use as a risk stratification biomarker for AKI has been hypothe-
sized. Not surprisingly, studies in both children and adults un-
dergoing cardiac surgery show that those with low levels of
THP preoperatively have the greatest risk of AKI postopera-
tively [90–92]. Studies are needed that utilize THP levels to
risk-stratify persons at increased risk of AKI and target preven-
tion strategies.
Elegant laboratory studies have demonstrated that increas-
ing concentrations of THP inhibit bacterial growth and
THP/ mice have an increased risk for developing bladder
infections with greater evidence of histological damage than
THPþ/þ mice [20, 21, 82, 93]. Supporting this is a large cohort
study demonstrating that persons with high urinary THP have
a significantly lower risk of UTI events compared with those in
those with the lowest THP [94]. Furthermore, THP may also be
important in preventing the development of bacteremia in
those with UTI [95].
Serum THP
A number of studies have reported positive correlations be-
tween serum/plasma THP levels and kidney function assessed
using GFR [51, 71]. In a cohort of 426 persons with different
stages of CKD, plasma THP showed very good ability to iden-
tify those with at least CKD Stage 3 [71]. Lower levels of serum
THP may identify early kidney function loss even when serum
creatinine values are still within a seemingly normal range (71–
106mmol/L) [67]. Serum THP levels were lower in patients
with CKD, albuminuria and hypertension [67] and were in-
versely associated with the development of incident CKD. Even
in persons who have undergone kidney transplants, lower levels
of serum THP were associated with double the risk of graft loss
after multiple adjustments for confounders [96]. Higher THP
levels in the serum are also associated with better CVD and
mortality outcomes [50, 70]. Taken together, this growing body
of compelling evidence suggests that the presence of high levels
of THP in the urine and serum is associated with better kidney,
CVD and mortality outcomes.
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INTERPRETING THP LEVELS IN KIDNEY
DISEASE
Based on this discussion, interpretation of the levels and
changes in THP measurements is shown in Figure 3. Both uri-
nary and serum/plasma THP can be measured using commer-
cially available enzyme-linked immunosorbent assays
(ELISAs). As discussed above, both measurements correlate
with kidney function and could be useful. We advocate the use
of plasma or serum THP since THP in the circulation is mono-
meric and less prone to degradation compared with urine. Both
of these factors could reduce the variability in measurements.
However, in advanced CKD, measuring 24-h urine THP may
have some advantages, as discussed above. Of note, there are
limited data on the level of THP in glomerulonephritis such as
systemic lupus erythematosus [68]. The available evidence sug-
gests that serum THP levels are lower in patients with kidney
involvement and injury, but more data are needed to explain
how measurements of THP could be used to monitor disease
activity and kidney involvement.
OPPOSING EFFECTS BETWEEN UMOD
PROMOTER REGION SNPS AND THE
EXPRESSION OF THP ON KIDNEY
FUNCTION: AN EXPRESSION
QUANTITATIVE TRAIT LOCI EFFECT ON
NEIGHBORING GENES?
One of the areas of debate recently has been the opposing effect
on kidney function between the level of expression of THP and
the presence of particular SNPs in the UMOD gene promoter
area uncovered from genome wide association studies (GWAS)
studies [97, 98]. We believe that the confusion developed be-
cause of data interpretation. The major alleles in variants
rs12917707 and rs4293393, which are in linkage disequilibrium,
are associated with an increased risk of kidney disease com-
pared with the minor alleles. In addition, these upstream var-
iants that increase the risk positively affect the level of THP
expression [60]. By transitivity, it has been proposed that in-
creased risk of the major alleles occurs through increased THP
expression. However, what is strikingly inconsistent with this
inference is that in the presence of the major allele, increased
expression of THP is paradoxically associated with protection,
independent of renal function and even in patients with normal
kidney function [50, 67, 68, 70]. This strongly suggests that al-
though risk variants can regulate THP expression, the effect of
these SNPs on kidney risk is independent of THP expression
and likely to offset the change in risk imparted by THP expres-
sion [50, 67]. Can SNPs upstream of the UMOD gene regulate
other genes that are involved in CKD?
Indeed, emerging understanding of gene regulatory elements
suggests that each gene could have multiple regulatory elements
that explain a fraction of its expression [expression quantitative
trait loci (eQTLs)] [99–102]. eQTLs can regulate multiple genes
within a close distance within a chromosome (e.g. 1 megabase;
cis-eQTL effect) or even more distantly (even on separate chro-
mosomes; trans-eQTL). The variability of eQTL effects for a
specific regulatory element is also likely to be tissue specific
[99]. For the case of the UMOD gene, multiple loci have been
implicated in its expression [103]. In addition to the variants
rs12917707 upstream of UMOD on chromosome 16, variant
rs12446492 in the neighboring PDILT gene or even variants in
KCNJ1, SORL1 (both on chromosome 11) and CAB39 (chro-
mosome 2) are associated with urinary THP levels [103].
Furthermore, multiple genes neighboring the UMOD gene
(such as ACSM2A/2B) are also enriched in the kidney and dis-
play an expression profile that is tightly linked with kidney
FIGURE 3: Interpretation of THP levels in clinical settings. THP can be measured either in the blood or in the serum. During acute illness or
chronic disease, serial measurements of THP may be more informative than a single measurement. This figure does not account for the pres-
ence of minor risk genetic SNP variants in the promoter area of THP, which alter THP expression and have an independent effect on kidney
disease risk.
Uromodulin (Tamm–Horsfall protein) 39
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article-abstract/35/1/33/5289516 by IU
PU
I U
niversity Library user on 17 M
arch 2020
function, suggesting a role in regulating kidney disease [102].
Based on this evidence, it is very likely that risk variants in the
UMOD promoter area regulate multiple neighboring or distal
genes involved in kidney disease [57, 99, 102]. We and other
groups proposed that this is likely to occur through the intricate
network of transcription factors that bind these regulatory
DNA motifs and are likely to coregulate gene expression [1, 57,
102]. Therefore a variant that alters the binding of certain tran-
scription factors and hinders or potentiates initiation complex
activation for one gene will concomitantly alter the expression
of other genes by altering the availability of functionally linked
transcription factors. A conceptual model of such regulation is
shown in Figure 4. In summary, as scientific discoveries unravel
the intricate and complex regulation of CKD risk-associated
transcripts, we caution against a simplified or fragmented ex-
planation of the mechanism underlying how risk variants in
regulatory elements are linked with kidney disease.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
As the most abundant protein in healthy human urine, THP
has recently received the level of attention that it rightly
deserves. The investigative efforts have been tremendously re-
warding, as we now know with some certainty that THP is a
multifunctional protein that plays indispensable roles in urinary
and systemic homeostasis and whose structural and functional
alterations can lead to a range of kidney and urinary diseases.
Investigators in the field can take pride in their perseverance in
studying a protein that was discovered almost 70 years ago and
which many regard as no longer attractive. Looking forward,
we must guard against the notion that there is not much else to
learn about THP or that THP is only a surrogate marker for
nephron mass. In fact, we are at the beginning stage of unravel-
ing the systemic effects of THP through its release in the circu-
lation. The kidney is known to produce erythropoietin, a
hormone that will determine the production of red cells and ox-
ygen delivery to the entire circulation. Therefore it is not unrea-
sonable to propose, based on the mounting evidence, that THP
is another hormone-like peptide produced by the kidney that
shapes systemic immunity and inflammatory signaling balance.
Furthermore, many critically important questions remain
unanswered. For instance, what is the functional significance of
the high expression of THP in TAL but the absent expression of
THP in the macula densa? What underlies the switch of THP
from the default apical membrane targeting to the basolateral
domain during renal ischemia and other conditions that predi-
cate the release of THP into the circulation? Is it because of the
intrinsic factors, that is, structural alterations in THP or
changes in the intracellular environment of TAL cells? Exactly
how is THP expression regulated by salt and water intake and
how do the changes in THP levels alter the apical translocation
and activity of NKCC2? How does THP expression within a
specific nephron correlate with the functional status of that par-
ticular nephron? In what clinical settings can THP serve as a
predictor of patient outcome? More importantly, can the levels
of THP be upregulated to serve therapeutic purposes? Similarly,
can structural defects caused by misfolding of mutated THP be
corrected by chemical chaperones? Answers to some of these
questions will undoubtedly have direct translational values in
improving the clinical management of THP-related diseases.
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FIGURE 4: Model of eQTL interactions. (A) A network of transcrip-
tion factors (TFs) and associated initiation complex (IC) molecules
concomitantly regulate the expression of multiple neighboring genes
through interactions with gene regulatory elements (GRE). Through
this large network, the engagement of specific TFs with GREs (e.g.
TFa for Gene A) alter the availability and/or conformation of other
linked TFs (TFb and TFc for Genes B and C, respectively). This will
cause either enhancement or inhibition of transcription in these
neighboring genes. (B) Therefore, in the presence of a polymorphism
within a specific GRE, gene expression will be altered not only in the
area of immediate proximity (Gene A), but also in the other coregu-
lated distant genes.
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